標(biāo)題: Titlebook: Case-Based Gynecological Oncology; Kavita Singh,Bindiya Gupta Book 2023 The Editor(s) (if applicable) and The Author(s), under exclusive l [打印本頁(yè)] 作者: 磨損 時(shí)間: 2025-3-21 17:57
書目名稱Case-Based Gynecological Oncology影響因子(影響力)
作者: CRANK 時(shí)間: 2025-3-21 23:23 作者: 過份好問 時(shí)間: 2025-3-22 02:01 作者: Myosin 時(shí)間: 2025-3-22 08:39 作者: jaunty 時(shí)間: 2025-3-22 09:39
Development of Near-IR Angiographyistochemistry especially using CK7 and CK20 are the most commonly used antigens in differentiating between primary and metastatic ovarian tumours. Genetic testing is crucial for counselling and tailoring management. Treatment is mainly palliative chemotherapy while in select cases metastatectomy or 作者: AGOG 時(shí)間: 2025-3-22 16:13 作者: AGOG 時(shí)間: 2025-3-22 18:34
Holography in Medical Diagnosticsumours are the most frequently diagnosed SCST and cause symptoms associated with hyperoestogenism. Juvenile and adult granulosa cell tumour have distinct clinical outcomes and it is imperative to distinguish them histologically. FOXL2 mutations are common in adult GCT which are distinctly absent in 作者: Acetaminophen 時(shí)間: 2025-3-22 22:50 作者: Classify 時(shí)間: 2025-3-23 04:39 作者: 含糊其辭 時(shí)間: 2025-3-23 07:27 作者: 完成 時(shí)間: 2025-3-23 12:46 作者: FLORA 時(shí)間: 2025-3-23 17:37
Behavioral and Structural Interfacese tumours are characterized by absence of p16 and presence of mutations in p53, KRAS, ARID 1A and PTEN. These tumours are aggressive, associated with higher recurrence rate and poor survival. Till now, the management strategies are same for both HPV dependent and independent tumours, although NHPV A作者: BLAZE 時(shí)間: 2025-3-23 19:55 作者: 哥哥噴涌而出 時(shí)間: 2025-3-24 00:37
Catherine H. Gebotys,Mohamed I. Elmasryncreasing rates of obesity. Other risk factors include diabetes, hypertension, polycystic ovarian syndrome (PCOS), nulliparity, and long term tamoxifen usage. Endometrial cancers have long been divided into oestrogen-dependent type I, and the less common, clinically aggressive, oestrogen-independent作者: 吹牛者 時(shí)間: 2025-3-24 03:12
North Atlantic ocean crust and Icelandrole of lymphadenectomy in mucinous and neuroendocrine tumours is debatable. Adjuvant treatment needs to be tailored to the underlying histology and (for NECs) may benefit from a specialist MDT opinion.作者: Peristalsis 時(shí)間: 2025-3-24 06:35
Development of Near-IR Angiographyistochemistry especially using CK7 and CK20 are the most commonly used antigens in differentiating between primary and metastatic ovarian tumours. Genetic testing is crucial for counselling and tailoring management. Treatment is mainly palliative chemotherapy while in select cases metastatectomy or cytoreductive surgery may be useful.作者: 騎師 時(shí)間: 2025-3-24 14:44
David Mendlovic,Naim Konforti,Emanuel Marom mild nuclear atypia without destructive stromal invasion. These account for 10–15% of all epithelial tumours. The most common subtypes are serous and mucinous tumours. Surgery is the mainstay of management and these are associated with better prognosis than invasive carcinomas.作者: 印第安人 時(shí)間: 2025-3-24 17:53
Catherine H. Gebotys,Mohamed I. Elmasryspecially possibility of more conservative surgery in specific patient groups, preferred surgical approach and lymph node evaluation strategies. Adjuvant radiotherapy with or without chemotherapy may be given on the basis of intermediate and high risk factors on surgicopathological assessment.作者: 摘要 時(shí)間: 2025-3-24 21:54 作者: addition 時(shí)間: 2025-3-25 00:07 作者: insolence 時(shí)間: 2025-3-25 06:05
Epithelial Ovarian Cancer: High Grade SerousEpithelial ovarian cancer mainly presents in advanced stage. In recent years, treatment has been revolutionized by changes in surgical and medical management, introduction of targeted therapies and biomarker directed therapies. This change in the treatment paradigm has had substantially improved survival statistics.作者: embolus 時(shí)間: 2025-3-25 10:39
Recurrent Ovarian CancerRecurrent ovarian cancer may be sensitive to platinum or platinum resistant. Management includes a combination of chemotherapy and targeted therapy. Secondary debulking surgery can be done in select cases where it is possible to achieve complete cytoreduction..This chapter will discuss clinical scenarios of recurrent ovarian cancer.作者: ANTE 時(shí)間: 2025-3-25 14:05 作者: fatuity 時(shí)間: 2025-3-25 16:56 作者: fatuity 時(shí)間: 2025-3-25 20:14 作者: 同位素 時(shí)間: 2025-3-26 02:03 作者: CLIFF 時(shí)間: 2025-3-26 05:21 作者: 幸福愉悅感 時(shí)間: 2025-3-26 11:27
Metastatic Ovarian Canceristochemistry especially using CK7 and CK20 are the most commonly used antigens in differentiating between primary and metastatic ovarian tumours. Genetic testing is crucial for counselling and tailoring management. Treatment is mainly palliative chemotherapy while in select cases metastatectomy or cytoreductive surgery may be useful.作者: FLIRT 時(shí)間: 2025-3-26 13:51
Borderline Ovarian Tumours: Early and Advance Stage: Serous, Mucinous, Micro Invasive Cancer, Invasi mild nuclear atypia without destructive stromal invasion. These account for 10–15% of all epithelial tumours. The most common subtypes are serous and mucinous tumours. Surgery is the mainstay of management and these are associated with better prognosis than invasive carcinomas.作者: 全部 時(shí)間: 2025-3-26 19:31 作者: Abnormal 時(shí)間: 2025-3-26 22:18
Book 2023 enhance their decision making skills..Case-Based Gynecological Oncology.?is a practical guide to clinical presentations of a range of conditions encountered in the field, making it a valuable resource for all clinicians who encounter these patients in their day-to-day practice..作者: 檔案 時(shí)間: 2025-3-27 01:09
Advanced Stage Cervical Cancerions including diversion stoma, ureteric or colonic stenting, and nephrostomies should be considered for cancer spreading to adjacent organs. This chapter will discuss management of various clinical scenarios of advanced cervical cancer.作者: 承認(rèn) 時(shí)間: 2025-3-27 08:50
Book 2023in clinical gynecological oncology. It emphasizes the importance of a holistic approach to tackling difficult and unique clinical presentations. Each chapter presents a specific pathology and features descriptions of clinical scenarios and presentations that are both commonly and rarely encountered.作者: fixed-joint 時(shí)間: 2025-3-27 10:59 作者: 描繪 時(shí)間: 2025-3-27 14:59 作者: 異常 時(shí)間: 2025-3-27 19:02
Catherine H. Gebotys,Mohamed I. Elmasryions including diversion stoma, ureteric or colonic stenting, and nephrostomies should be considered for cancer spreading to adjacent organs. This chapter will discuss management of various clinical scenarios of advanced cervical cancer.作者: seroma 時(shí)間: 2025-3-28 00:43 作者: 不可知論 時(shí)間: 2025-3-28 04:41 作者: LATHE 時(shí)間: 2025-3-28 10:10
Introduction and the ophiolite model chemoresistance and the role of chemotherapy in both neoadjuvant and adjuvant setting is debatable, yet chemotherapy is recommened in advanced stages. HT can be administered as adjuvant or maintenance treatment after cytoreduction.作者: 評(píng)論性 時(shí)間: 2025-3-28 13:07 作者: URN 時(shí)間: 2025-3-28 15:33 作者: 昏睡中 時(shí)間: 2025-3-28 22:16 作者: Aggregate 時(shí)間: 2025-3-29 00:14
Behavioral and Structural Interfaceshigher recurrence rate and poor survival. Till now, the management strategies are same for both HPV dependent and independent tumours, although NHPV A adenocarcinomas have variable responses to standard treatment.作者: 防水 時(shí)間: 2025-3-29 06:56 作者: 拋媚眼 時(shí)間: 2025-3-29 11:10
Catherine H. Gebotys,Mohamed I. Elmasryn usage. Endometrial cancers have long been divided into oestrogen-dependent type I, and the less common, clinically aggressive, oestrogen-independent type II. This chapter will discuss various clinical cases of early stage type 1 endometrial cancers.作者: 舞蹈編排 時(shí)間: 2025-3-29 14:32
Management of Adnexal Massesor markers play an important role to determine the presence and type of malignant ovarian mass. Various triaging models like Risk of malignancy index, ADNEX model and ORADS can be used to triage masses to be referred to gynae oncologist.作者: resistant 時(shí)間: 2025-3-29 17:32 作者: MAUVE 時(shí)間: 2025-3-29 20:51 作者: POLYP 時(shí)間: 2025-3-30 02:03
Stromal Tumours of Ovary: Granulosa Cell Tumours, Leydig Cell Tumours, Thecomanct clinical outcomes and it is imperative to distinguish them histologically. FOXL2 mutations are common in adult GCT which are distinctly absent in juvenile GCT. Sertoli-Leydig cell tumours (SLCT) are a rarer tumour and show hyperandrogenic effects. Surgery remains the mainstay of treatment in all stromal tumours.作者: atrophy 時(shí)間: 2025-3-30 05:04 作者: Badger 時(shí)間: 2025-3-30 10:48 作者: forager 時(shí)間: 2025-3-30 15:05
Diagnostic Pathways of Postmenopausal Bleedingndometrial sampling with or without hysteroscopy is recommended. Hysteroscopy is offered to women with ET of ≥10?mm, focal lesion on TVS, recurrent PMB irrespective of the ET, or inadequate endometrial biopsy.作者: 充氣球 時(shí)間: 2025-3-30 17:02 作者: 討好女人 時(shí)間: 2025-3-30 22:02 作者: 同步左右 時(shí)間: 2025-3-31 01:14
Management of Adnexal Massese an adnexal mass into possibly benign or malignant. The IOTA simple rules and ORADS are two classification systems for adnexal masses on imaging. Tumor markers play an important role to determine the presence and type of malignant ovarian mass. Various triaging models like Risk of malignancy index,作者: 使?jié)M足 時(shí)間: 2025-3-31 08:29 作者: 考得 時(shí)間: 2025-3-31 09:20 作者: senile-dementia 時(shí)間: 2025-3-31 13:46
Platinum Resistant Ovarian Cancerlth related quality of life and use of maintenance therapy with bevacizumab and PARP inhibitors. Treatment of early recurrence (<6?months of completion of primary chemotherapy) usually consists of single agent non platinum drugs like liposomal doxorubicin, paclitaxel, etoposide and the overall respo作者: Kernel 時(shí)間: 2025-3-31 19:40
Metastatic Ovarian Canceristochemistry especially using CK7 and CK20 are the most commonly used antigens in differentiating between primary and metastatic ovarian tumours. Genetic testing is crucial for counselling and tailoring management. Treatment is mainly palliative chemotherapy while in select cases metastatectomy or 作者: Commemorate 時(shí)間: 2025-4-1 00:42 作者: 昏暗 時(shí)間: 2025-4-1 04:22
